UTHR Stock Chart & Stats
$9680.00
$0.00(0.00%)
At close: 4:00 PM EDT
$9680.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$7,961.00 - $9,884.33
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$482.43B
Enterprise Value$22.15B
Total Cash (Recent Filing)$2.66B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)19.8
Beta0.06
Next Earnings
Nov 04, 2026EPS Estimate
112.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)30.23
Shares Outstanding42,890,694
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.16
Price to Book (P/B)3.04
Price to Sales (P/S)6.78
P/FCF Ratio20.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$12,636.22Price Target Upside30.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)496.54
Revenue Forecast (FY)$59.53B
Bulls Say, Bears Say
Bulls Say
High Profitability And Cash GenerationUnited Therapeutics combines unusually high profitability with substantial cash generation, giving it capacity to fund clinical development, commercial expansion and organ-manufacturing initiatives internally. Strong cash conversion also improves resilience and supports flexible capital allocation over the next several quarters.
Conservative Balance SheetAn essentially debt-free balance sheet gives United Therapeutics significant financial flexibility while reducing interest and refinancing pressure. That position can support investment in pipeline programs, facilities and strategic opportunities without requiring heavy reliance on external financing during periods of business volatility.
Broadening Clinical And Organ PipelineMultiple positive clinical readouts and regulatory filings create potential avenues for expanding beyond the existing PAH franchise. Ralinepag, Tyvaso in IPF, additional inhalation devices and xenotransplantation programs could diversify future growth and enlarge the company’s addressable markets.
Bears Say
Sharp Recent Revenue DeclineThe sharp TTM revenue decline indicates that recent commercial performance has been uneven despite strong historical profitability. If this volatility persists, it could reduce operating leverage, make investment planning more difficult and delay the conversion of pipeline progress into sustained company-wide growth.
Tyvaso Faces Growing CompetitionCompetitive pressure on Tyvaso matters because the product generated approximately 58% of Q2 revenue, making the franchise central to near-term results. Greater competition could constrain volume growth, market share and commercial leverage even if patient starts and referrals continue increasing.
Revenue And Regulatory Timing UncertaintyWith 2026 guidance not reaffirmed and approval timing unresolved, the timing of revenue growth remains difficult to forecast. Delays in regulatory decisions or launch execution could postpone contributions from new indications and leave near-term results more dependent on the pressured existing franchise.
United Therapeutics News
UTHR FAQ
What was United Therapeutics’s price range in the past 12 months?
United Therapeutics lowest stock price was $7961.00 and its highest was $9884.33 in the past 12 months.
What is United Therapeutics’s market cap?
United Therapeutics’s market cap is $482.43B.
When is United Therapeutics’s upcoming earnings report date?
United Therapeutics’s upcoming earnings report date is Nov 04, 2026 which is in 4 days.
How were United Therapeutics’s earnings last quarter?
United Therapeutics released its earnings results on Aug 05, 2026. The company reported $136.58 earnings per share for the quarter, beating the consensus estimate of $128.915 by $7.665.
Is United Therapeutics overvalued?
According to Wall Street analysts United Therapeutics’s price is currently Undervalued.
Does United Therapeutics pay dividends?
United Therapeutics does not currently pay dividends.
What is United Therapeutics’s EPS estimate?
United Therapeutics’s EPS estimate is 112.85.
How many shares outstanding does United Therapeutics have?
United Therapeutics has 42,890,694 shares outstanding.
What happened to United Therapeutics’s price movement after its last earnings report?
United Therapeutics reported an EPS of $136.58 in its last earnings report, beating expectations of $128.915. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of United Therapeutics?
Currently, no hedge funds are holding shares in MX:UTHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
United Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12,636.22 (30.54% Upside)
$12,636.22 (30.54% Upside)
Blogger Sentiment
Neutral
MX:UTHR Sentiment 55%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.01%
12-Months-Change
Fundamentals
Return on Equity
20.18%
Trailing 12-Months
Asset Growth
-8.70%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
United Therapeutics
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
UTHR Company Deck
UTHR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced significant near-term commercial challenges with very strong clinical and pipeline momentum. Short-term results (Q2 revenue) came in below expectations and Tyvaso faces competitive pressure, creating uncertainty for 2026 revenue. Offsetting this are multiple highly positive Phase III outcomes, major regulatory filings (ralinepag NDA and Tyvaso IPF sNDA), planned additional filings (DPI and SMI), near-complete enrollment for a large PPF trial, aggressive commercial investments (≈100% sales force expansion), and progress across a differentiated xenotransplantation/organ pipeline. Given the material potential of the recent clinical wins and the company’s execution initiatives that could drive meaningful upside in 2027 and beyond, the positives outweigh the near-term lowlights.View all MX:UTHR earnings summariesUTHR Revenue Breakdown
53.01% Tyvaso
21.26% Remodulin
15.44% Orenitram
8.55% Unituxin
1.75% Other
UTHR Stock 12 Month Forecast
Average Price Target
$12,636.22
▲(30.54% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Insmed
―
Jazz Pharmaceuticals
―
BridgeBio Pharma
―